We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-6.58%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.73B
AUM Growth
-$470M
Cap. Flow
-$39.5M
Cap. Flow %
-1.06%
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
23
Closed
9

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
PEN icon
Penumbra
PEN
+$38.2M
3
BPMC
Blueprint Medicines
BPMC
+$26.6M
4
ABOS icon
Acumen Pharmaceuticals
ABOS
+$17.4M
5
AMGN icon
Amgen
AMGN
+$17M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$44.5M
2
PODD icon
Insulet
PODD
+$40.1M
3
CNMD icon
CONMED
CNMD
+$27.9M
4
ABCM
Abcam PLC
ABCM
+$26M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.04%
2 Consumer Staples 1.17%
3 Industrials 0.83%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLRN
101
DELISTED
ACELYRIN
SLRN
$1.44M 0.04%
141,876
– –
FATE icon
102
Fate Therapeutics
FATE
$318M
$1.3M 0.03%
612,215
– –
CGEN icon
103
Compugen
CGEN
$224M
$1.2M 0.03%
1,289,990
– –
THRX
104
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.18M 0.03%
437,329
– –
DSGN icon
105
Design Therapeutics
DSGN
$903M
$1.09M 0.03%
460,391
– –
VINC
106
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$901K 0.02%
44,586
– –
KNTE
107
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$568K 0.02%
405,811
-341,162
-46% -$819K
NKTX icon
108
Nkarta
NKTX
$164M
$461K 0.01%
331,571
– –
CRVO icon
109
CervoMed
CRVO
$41.4M
$370K 0.01%
+80,033
New +$403K
NVTA
110
DELISTED
Invitae Corporation
NVTA
$354K 0.01%
585,659
-1,064,836
-65% -$1.11M
TLPH icon
111
Talphera
TLPH
$73.7M
$184K ﹤0.01%
316,460
– –
TPST icon
112
Tempest Therapeutics
TPST
$18.4M
$163K ﹤0.01%
41,247
– –
BCEL
113
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$94.6K ﹤0.01%
362,530
– –
SPRO icon
114
Spero Therapeutics
SPRO
$70.6M
$69.4K ﹤0.01%
57,373
-612,160
-91% -$848K
GMDA
115
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$53.6K ﹤0.01%
52,015
-663,008
-93% -$847K
NUVB.WS
116
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.4K ﹤0.01%
134,028
– –
ALT icon
117
Altimmune
ALT
$587M
– –
-223,255
Closed -$788K
ANAB icon
118
AnaptysBio
ANAB
$1.67B
– –
-341,637
Closed -$6.95M
BDTX icon
119
Black Diamond Therapeutics
BDTX
$114M
– –
-563,233
Closed -$2.84M
BHVN icon
120
Biohaven
BHVN
$2.12B
– –
-401,624
Closed -$9.61M
CNMD icon
121
CONMED
CNMD
$1.5B
– –
-205,000
Closed -$27.9M
GH icon
122
Guardant Health
GH
$22.5B
– –
-200,000
Closed -$7.16M
NVCR icon
123
NovoCure
NVCR
$2.03B
– –
-125,000
Closed -$5.19M
PRTK
124
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-1,734,037
Closed -$3.83M
KDNY
125
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-396,280
Closed -$15.2M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rock Springs Capital Management held 129 positions worth $3.73B, down 11% from $4.2B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management's Q3 2023 filing shows 6 new, 41 increased, 23 reduced and 9 closed positions. Its largest new stake was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M. The largest sale was argenx, an estimated $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2023 buy was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2023, an estimated $46.8M increase.
  • Rock Springs Capital Management's biggest Q3 2023 reduction was argenx, cutting an estimated $44.5M.
  • Rock Springs Capital Management fully exited CONMED in Q3 2023, selling an estimated $27.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.73B portfolio in Q3 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 9 in Q3 2023.
  • Rock Springs Capital Management's portfolio value fell 11% quarter-over-quarter to $3.73B.

Based on Rock Springs Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.